Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05135975 · ClinicalTrials.gov registry record · Phase 2
A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors
A Phase 2 study of Sarcoma and Neuroblastoma, sponsored by Nationwide Children's Hospital.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 86
- Enrollment target
- 6
- Study locations
NCT05135975: Recruiting Phase 2 study of Sarcoma and Neuroblastoma, sponsored by Nationwide Children's Hospital.
NCT05135975 is a Phase 2 study of Sarcoma and Neuroblastoma that is actively recruiting participants, run by Nationwide Children's Hospital. The registered enrollment target is 86 participants, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (91% lower). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05135975, a Phase 2 study of Sarcoma and Neuroblastoma, is actively recruiting participants, sponsored by Nationwide Children's Hospital.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 86 participants
- Enrollment target
- 6
- Study locations
Study Summary
This study will expand the types of pediatric cancers being evaluated for response to cabozantinib. The current COG study is restricted to Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, Wilms tumor, and a handful of uncommon tumors. The proposed study will extend this evaluation to tumors that have been shown to either express known targets of cabozantinib or with preclinical evidence of efficacy, including specifically neuroblastomas. These tumors have high morbidity and mortality, particularly in the relapse setting, and few or no proven therapeutic options. As such, evaluation of cabozantinib in these studies is warranted. The study hypothesizes that use of cabozantinib in patients with ultra-high-risk pediatric solid tumors with minimal disease burden, as defined in the inclusion criteria below, can prevent and/or slow recurrent tumor formation in pediatric solid tumors and thereby significantly extend the period of disease control and/or induce a durable cure.
Primary Outcome
Defined as the time from diagnosis until the date of disease progression
Conditions Studied
Interventions
- DRUG Cabozantinib
Study Locations (6)
Alabama
- Children's Hospital of Alabama/UAB - Birmingham
Colorado
- Children's Hospital of Colorado - Aurora
District of Columbia
- Children's National Medical Center - Washington D.C.
New York
- Children's Hospital at Montefiore - The Bronx
Ohio
- Nationwide Children's Hospital - Columbus
Utah
- Primary Children's Hospital - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2022-07-20 |
| Est. Completion | 2029-12 |
| Phase | Phase 2 |
What NCT05135975 shows while recruiting
NCT05135975 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 86 participants, a relatively small participant target, below the 921-participant average among 122 other Sarcoma trials with a reported enrollment target (91% lower).
The record links to 2 conditions, with Sarcoma appearing as the primary indexed condition, and to 1 intervention - of which Cabozantinib is the first listed.
NCT05135975 lists 6 locations in 6 states (Alabama, Colorado, District of Columbia).
Frequently Asked Questions
What is clinical trial NCT05135975 about?
NCT05135975 is a clinical study titled "A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors". This study will expand the types of pediatric cancers being evaluated for response to cabozantinib. The current COG study is restricted to Ewing sarcoma, osteosarcoma, rhabdomyosarcoma, Wilms tumor, and a handful of uncommon tumors. The proposed study will extend this evaluation to tumors that have ...
What is the current status of trial NCT05135975?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 86 participants. The study started on 2022-07-20. Estimated completion is 2029-12.
What conditions does trial NCT05135975 study?
This clinical trial studies the following conditions: Sarcoma, Neuroblastoma.
What interventions are being tested in trial NCT05135975?
The interventions under investigation include: Cabozantinib (DRUG).
Who is sponsoring clinical trial NCT05135975?
This trial is sponsored by Nationwide Children's Hospital, which has 188 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05135975 being conducted?
This trial has 6 study locations across Alabama, Colorado, District of Columbia, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sarcoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05135975's enrollment target sits among peer trials
86 47th of 122 higher than 76 of 122 other Sarcoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sarcoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
RECRUITING · Phase 2
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
RECRUITING · Phase 2
-
Fluorescent Intra-operative Tumor Margin Examination
RECRUITING · Phase 2
-
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
RECRUITING · Phase 2
-
Phase II Trial of Lung Chemoemobolization
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01639508 · 86 participants · Phase 2
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- NCT03519269 · 86 participants · NA
Navio Robotic Versus Conventional Total Knee Arthroplasty
- NCT04132999 · 86 participants · NA
PAP for Children With DS and OSAS
- NCT04545957 · 86 participants · NA
Jump: MR Simulation For Radiation Therapy Master Protocol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy